Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
farletuzumab ecteribulin
- Development stage
- Phase 2
- Lead developer
- Eisai
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Farletuzumab ecteribulin is an investigational **folate receptor alpha-targeting antibody-drug conjugate** developed by Eisai. It comprises the humanized IgG1 anti-folate receptor alpha antibody farletuzumab conjugated through an enzymatically cleavable, cathepsin B-cleavable linker to the microtubule-dynamics inhibitor eribulin. Following binding to folate receptor alpha-positive tumor cells and internalization, linker cleavage releases eribulin, which disrupts microtubule dynamics and produces cytotoxic antitumor activity; released payload may also contribute to a bystander effect. The agent has been evaluated in ovarian, endometrial, non-small cell lung, primary peritoneal, fallopian tube, and triple-negative breast cancers. Eisai regained sole global development and commercialization rights after its collaboration with Bristol Myers Squibb ended on July 1, 2024. ([eisai.com](https://www.eisai.com/news/2024/news202448.html))
- Other names
- FZEC
02
Targets
FOLR1 (FRα)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on farletuzumab ecteribulin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on farletuzumab ecteribulin.